Lv796
3580 积分 2024-07-23 加入
SAT-655 Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials
2天前
已完结
Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis ( MASH )
2天前
已完结
Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD)
3天前
已完结
Effect of resmetirom on lipid profile and adiponectin levels
3天前
已完结
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs
4天前
已完结
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic dysfunction–associated Steatotic Liver Disease in Clinical Practice
4天前
求助中
Mechanisms and therapeutic insights into MASH-associated fibrosis
4天前
已完结
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
4天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
8天前
已完结
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
22天前
已完结
皖公网安备34019202002308
